Biologics in inflammatory disease: infliximab associated risk of lymphoma development.
Authors:
- 1 May 2005
- Vol. 54 (5) , 732-3
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patientsArthritis & Rheumatism, 2004
- Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm CountyGut, 2004
- The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patientsGastroenterology, 2004
- CD30+ T-cell lymphoma in a patient with psoriasis treated with ciclosporin and infliximabBritish Journal of Dermatology, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximabRheumatology, 2002
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- The relationship between infliximab treatment and lymphoma in Crohn's diseaseGastroenterology, 1999
- Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's diseaseGastroenterology, 1999